Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

This study is currently recruiting participants.
Verified August 2013 by Dartmouth-Hitchcock Medical Center
Sponsor:
Collaborators:
Cephalon
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT01234766
First received: October 6, 2010
Last updated: August 26, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)